Industry Research Reports
Home > Reports > Pharma & Healthcare > Global Varicella Vaccine Market Outlook, In‑Depth Analysis & Forecast to 2031
Global Varicella Vaccine Market Outlook, In‑Depth Analysis & Forecast to 2031
Industry: Pharma & Healthcare
Published Date: 2025-09-11
Pages: 149 Pages
Report ld: 5038681
Request Sample
Customized Report
- Description
- Table of Contents
- Table of Figures
- Related Reports
PDF Download
- Description
- Table of Contents
- Table of Figures
- Related Reports
- PDF Download
Varicella Vaccine Market Size(US$)
CAGR 2025-2031
7.8%
Market Size,2031
USD 8,137
Million
Market Snapshot
Market Size in 2025 (Value)
US$ 5,185 million
Market Forecast in 2031(Value)
US$ 8,137 million
CAGR
7.8%
Years Considered
2020-2031
Base Year
2025
Forecast Period
2025-2031
Source: Secondary research, interviews with experts, and QYResearch analysis
The global Varicella Vaccine market is projected to grow from US$ 4845 million in 2024 to US$ 8137 million by 2031, at a CAGR of 7.8% (2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Varicella vaccine, also known as chickenpox vaccine, is a vaccine that protects against chickenpox. One dose of vaccine prevents 95% of moderate disease and 100% of severe disease. Two doses of vaccine is more effective than one. If given to those who are not immune within five days of exposure to chickenpox it prevents most cases of disease. Vaccinating a large portion of the population also protects those who are not vaccinated. It is given by injection just under the skin
Global Varicella Vaccine key players include Merck, Shanghai Institute, Changsheng, Keygen, GSK, etc.
Asia is the largest market, with a share over 35%, followed by US and Europe, both have a share over 55%.
In terms of product, Freeze-Dried Powder is the largest segment, with a share over 50%. And in terms of application, the largest application is Kids Injection, followed by Adults Injection, etc.
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Varicella Vaccine market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
MARKET SEGMENTATION
By Company
- Merck
- GSK
- Shanghai Institute
- BCHT
- Changsheng
- Keygen
- Green Cross
- Biken
Consumption by Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Segment by Type
- Injection
- Freeze-Dried Powder
Segment by Application
- Kids Injection
- Adults Injection
CHAPTER OUTLINE
Chapter 1: Defines the Varicella Vaccine study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
WHY THIS REPORT
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
QYRESEARCH'S STRENGTHS
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
Market entry risks/opportunities by region
We identify regional market threats and growth prospects to guide your overseas layout.
Product mix optimization based on local practices
We adjust product portfolios in line with local consumption habits.
Competitor tactics in fragmented vs. consolidated markets
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
Full Research Coverage
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
19 Years Industry Expertise
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
24/7 Fast Report Delivery
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
Localized Strategic Analysis
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
Market entry risks/opportunities by region
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
Market entry risks/opportunities by region
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
TABLE OF CONTENTS
1 Study Coverage
1.1 Introduction to Varicella Vaccine: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Varicella Vaccine Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Injection
1.2.3 Freeze-Dried Powder
1.3 Market Segmentation by Application
1.3.1 Global Varicella Vaccine Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Kids Injection
1.3.3 Adults Injection
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Varicella Vaccine Revenue Estimates and Forecasts 2020-2031
2.2 Global Varicella Vaccine Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Varicella Vaccine Sales Estimates and Forecasts 2020-2031
2.4 Global Varicella Vaccine Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Varicella Vaccine Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Varicella Vaccine Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Injection Market Size by Manufacturers
3.5.2 Freeze-Dried Powder Market Size by Manufacturers
3.6 Global Varicella Vaccine Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Varicella Vaccine Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Varicella Vaccine Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Varicella Vaccine Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Varicella Vaccine Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Varicella Vaccine Sales and Revenue by Type (2020-2031)
6.4 North America Varicella Vaccine Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Varicella Vaccine Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Varicella Vaccine Sales and Revenue by Type (2020-2031)
7.4 Europe Varicella Vaccine Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Varicella Vaccine Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Varicella Vaccine Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Varicella Vaccine Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Varicella Vaccine Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Varicella Vaccine Sales and Revenue by Type (2020-2031)
9.4 Central and South America Varicella Vaccine Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Varicella Vaccine Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Varicella Vaccine Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Varicella Vaccine Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Varicella Vaccine Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Merck
11.1.1 Merck Corporation Information
11.1.2 Merck Business Overview
11.1.3 Merck Varicella Vaccine Product Models, Descriptions and Specifications
11.1.4 Merck Varicella Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Merck Varicella Vaccine Sales by Product in 2024
11.1.6 Merck Varicella Vaccine Sales by Application in 2024
11.1.7 Merck Varicella Vaccine Sales by Geographic Area in 2024
11.1.8 Merck Varicella Vaccine SWOT Analysis
11.1.9 Merck Recent Developments
11.2 GSK
11.2.1 GSK Corporation Information
11.2.2 GSK Business Overview
11.2.3 GSK Varicella Vaccine Product Models, Descriptions and Specifications
11.2.4 GSK Varicella Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 GSK Varicella Vaccine Sales by Product in 2024
11.2.6 GSK Varicella Vaccine Sales by Application in 2024
11.2.7 GSK Varicella Vaccine Sales by Geographic Area in 2024
11.2.8 GSK Varicella Vaccine SWOT Analysis
11.2.9 GSK Recent Developments
11.3 Shanghai Institute
11.3.1 Shanghai Institute Corporation Information
11.3.2 Shanghai Institute Business Overview
11.3.3 Shanghai Institute Varicella Vaccine Product Models, Descriptions and Specifications
11.3.4 Shanghai Institute Varicella Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Shanghai Institute Varicella Vaccine Sales by Product in 2024
11.3.6 Shanghai Institute Varicella Vaccine Sales by Application in 2024
11.3.7 Shanghai Institute Varicella Vaccine Sales by Geographic Area in 2024
11.3.8 Shanghai Institute Varicella Vaccine SWOT Analysis
11.3.9 Shanghai Institute Recent Developments
11.4 BCHT
11.4.1 BCHT Corporation Information
11.4.2 BCHT Business Overview
11.4.3 BCHT Varicella Vaccine Product Models, Descriptions and Specifications
11.4.4 BCHT Varicella Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 BCHT Varicella Vaccine Sales by Product in 2024
11.4.6 BCHT Varicella Vaccine Sales by Application in 2024
11.4.7 BCHT Varicella Vaccine Sales by Geographic Area in 2024
11.4.8 BCHT Varicella Vaccine SWOT Analysis
11.4.9 BCHT Recent Developments
11.5 Changsheng
11.5.1 Changsheng Corporation Information
11.5.2 Changsheng Business Overview
11.5.3 Changsheng Varicella Vaccine Product Models, Descriptions and Specifications
11.5.4 Changsheng Varicella Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Changsheng Varicella Vaccine Sales by Product in 2024
11.5.6 Changsheng Varicella Vaccine Sales by Application in 2024
11.5.7 Changsheng Varicella Vaccine Sales by Geographic Area in 2024
11.5.8 Changsheng Varicella Vaccine SWOT Analysis
11.5.9 Changsheng Recent Developments
11.6 Keygen
11.6.1 Keygen Corporation Information
11.6.2 Keygen Business Overview
11.6.3 Keygen Varicella Vaccine Product Models, Descriptions and Specifications
11.6.4 Keygen Varicella Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Keygen Recent Developments
11.7 Green Cross
11.7.1 Green Cross Corporation Information
11.7.2 Green Cross Business Overview
11.7.3 Green Cross Varicella Vaccine Product Models, Descriptions and Specifications
11.7.4 Green Cross Varicella Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 Green Cross Recent Developments
11.8 Biken
11.8.1 Biken Corporation Information
11.8.2 Biken Business Overview
11.8.3 Biken Varicella Vaccine Product Models, Descriptions and Specifications
11.8.4 Biken Varicella Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.5 Biken Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Varicella Vaccine Industry Chain
12.2 Varicella Vaccine Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Varicella Vaccine Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Varicella Vaccine Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Varicella Vaccine Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Varicella Vaccine Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
TABLE OF FIGURES
List of Tables
Table 1. Global Varicella Vaccine Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Varicella Vaccine Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Varicella Vaccine Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Varicella Vaccine Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Varicella Vaccine Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Varicella Vaccine Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (M Doses)
Table 7. Global Varicella Vaccine Sales by Region (2020-2025) & (M Doses)
Table 8. Global Varicella Vaccine Sales by Region (2026-2031) & (M Doses)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Varicella Vaccine Sales by Manufacturers (2020-2025) & (M Doses)
Table 11. Global Varicella Vaccine Sales Share by Manufacturers (2020-2025)
Table 12. Global Varicella Vaccine Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Varicella Vaccine Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Varicella Vaccine by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Varicella Vaccine as of 2024)
Table 16. Global Varicella Vaccine Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Varicella Vaccine Average Selling Price (ASP) by Manufacturers (2020-2025) & (USD/Dose)
Table 18. Key Manufacturers Varicella Vaccine Manufacturing Base and Headquarters
Table 19. Global Varicella Vaccine Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Varicella Vaccine Sales by Type (2020-2025) & (M Doses)
Table 23. Global Varicella Vaccine Sales by Type (2026-2031) & (M Doses)
Table 24. Global Varicella Vaccine Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Varicella Vaccine Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Varicella Vaccine ASP by Type (2020-2031) & (USD/Dose)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Varicella Vaccine Sales by Application (2020-2025) & (M Doses)
Table 29. Global Varicella Vaccine Sales by Application (2026-2031) & (M Doses)
Table 30. Varicella Vaccine High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Varicella Vaccine Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Varicella Vaccine Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Varicella Vaccine ASP by Application (2020-2031) & (USD/Dose)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Varicella Vaccine Growth Accelerators and Market Barriers
Table 37. North America Varicella Vaccine Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Varicella Vaccine Sales (M Doses) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Varicella Vaccine Growth Accelerators and Market Barriers
Table 40. Europe Varicella Vaccine Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Varicella Vaccine Sales (M Doses) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Varicella Vaccine Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Varicella Vaccine Sales (M Doses) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Varicella Vaccine Growth Accelerators and Market Barriers
Table 45. Southeast Asia Varicella Vaccine Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Varicella Vaccine Investment Opportunities and Key Challenges
Table 47. Central and South America Varicella Vaccine Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Varicella Vaccine Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Varicella Vaccine Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Merck Corporation Information
Table 51. Merck Description and Major Businesses
Table 52. Merck Product Models, Descriptions and Specifications
Table 53. Merck Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 54. Merck Sales Value Proportion by Product in 2024
Table 55. Merck Sales Value Proportion by Application in 2024
Table 56. Merck Sales Value Proportion by Geographic Area in 2024
Table 57. Merck Varicella Vaccine SWOT Analysis
Table 58. Merck Recent Developments
Table 59. GSK Corporation Information
Table 60. GSK Description and Major Businesses
Table 61. GSK Product Models, Descriptions and Specifications
Table 62. GSK Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 63. GSK Sales Value Proportion by Product in 2024
Table 64. GSK Sales Value Proportion by Application in 2024
Table 65. GSK Sales Value Proportion by Geographic Area in 2024
Table 66. GSK Varicella Vaccine SWOT Analysis
Table 67. GSK Recent Developments
Table 68. Shanghai Institute Corporation Information
Table 69. Shanghai Institute Description and Major Businesses
Table 70. Shanghai Institute Product Models, Descriptions and Specifications
Table 71. Shanghai Institute Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 72. Shanghai Institute Sales Value Proportion by Product in 2024
Table 73. Shanghai Institute Sales Value Proportion by Application in 2024
Table 74. Shanghai Institute Sales Value Proportion by Geographic Area in 2024
Table 75. Shanghai Institute Varicella Vaccine SWOT Analysis
Table 76. Shanghai Institute Recent Developments
Table 77. BCHT Corporation Information
Table 78. BCHT Description and Major Businesses
Table 79. BCHT Product Models, Descriptions and Specifications
Table 80. BCHT Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 81. BCHT Sales Value Proportion by Product in 2024
Table 82. BCHT Sales Value Proportion by Application in 2024
Table 83. BCHT Sales Value Proportion by Geographic Area in 2024
Table 84. BCHT Varicella Vaccine SWOT Analysis
Table 85. BCHT Recent Developments
Table 86. Changsheng Corporation Information
Table 87. Changsheng Description and Major Businesses
Table 88. Changsheng Product Models, Descriptions and Specifications
Table 89. Changsheng Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 90. Changsheng Sales Value Proportion by Product in 2024
Table 91. Changsheng Sales Value Proportion by Application in 2024
Table 92. Changsheng Sales Value Proportion by Geographic Area in 2024
Table 93. Changsheng Varicella Vaccine SWOT Analysis
Table 94. Changsheng Recent Developments
Table 95. Keygen Corporation Information
Table 96. Keygen Description and Major Businesses
Table 97. Keygen Product Models, Descriptions and Specifications
Table 98. Keygen Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 99. Keygen Recent Developments
Table 100. Green Cross Corporation Information
Table 101. Green Cross Description and Major Businesses
Table 102. Green Cross Product Models, Descriptions and Specifications
Table 103. Green Cross Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 104. Green Cross Recent Developments
Table 105. Biken Corporation Information
Table 106. Biken Description and Major Businesses
Table 107. Biken Product Models, Descriptions and Specifications
Table 108. Biken Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 109. Biken Recent Developments
Table 110. Key Raw Materials Distribution
Table 111. Raw Materials Key Suppliers
Table 112. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 113. Milestones in Production Technology Evolution
Table 114. Distributors List
Table 115. Market Trends and Market Evolution
Table 116. Market Drivers and Opportunities
Table 117. Market Challenges, Risks, and Restraints
Table 118. Research Programs/Design for This Report
Table 119. Key Data Information from Secondary Sources
Table 120. Key Data Information from Primary Sources
List of Figures
Figure 1. Varicella Vaccine Product Picture
Figure 2. Global Varicella Vaccine Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Injection Product Picture
Figure 4. Freeze-Dried Powder Product Picture
Figure 5. Global Varicella Vaccine Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 6. Kids Injection
Figure 7. Adults Injection
Figure 8. Varicella Vaccine Report Years Considered
Figure 9. Global Varicella Vaccine Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 10. Global Varicella Vaccine Revenue (2020-2031) & (US$ Million)
Figure 11. Global Varicella Vaccine Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 12. Global Varicella Vaccine Revenue Market Share by Region (2020-2031)
Figure 13. Global Varicella Vaccine Sales (2020-2031) & (M Doses)
Figure 14. Global Varicella Vaccine Sales (CAGR) by Region (2020-2031) (M Doses)
Figure 15. Global Varicella Vaccine Sales Market Share by Region (2020-2031)
Figure 16. Top 5 and Top 10 Manufacturers Varicella Vaccine Sales Volume Market Share in 2024
Figure 17. Global Varicella Vaccine Revenue Market Share Ranking (2024)
Figure 18. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 19. Injection Revenue Market Share by Manufacturer in 2024
Figure 20. Freeze-Dried Powder Revenue Market Share by Manufacturer in 2024
Figure 21. Global Varicella Vaccine Sales Market Share by Type (2020-2031)
Figure 22. Global Varicella Vaccine Revenue Market Share by Type (2020-2031)
Figure 23. Global Varicella Vaccine Sales Market Share by Application (2020-2031)
Figure 24. Global Varicella Vaccine Revenue Market Share by Application (2020-2031)
Figure 25. North America Varicella Vaccine Sales YoY (2020-2031) & (M Doses)
Figure 26. North America Varicella Vaccine Revenue YoY (2020-2031) & (US$ Million)
Figure 27. North America Top 5 Manufacturers Varicella Vaccine Sales Revenue (US$ Million) in 2024
Figure 28. North America Varicella Vaccine Sales Volume (M Doses) by Type (2020- 2031)
Figure 29. North America Varicella Vaccine Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 30. North America Varicella Vaccine Sales Volume (M Doses) by Application (2020-2031)
Figure 31. North America Varicella Vaccine Sales Revenue (US$ Million) by Application (2020-2031)
Figure 32. US Varicella Vaccine Revenue (2020-2031) & (US$ Million)
Figure 33. Canada Varicella Vaccine Revenue (2020-2031) & (US$ Million)
Figure 34. Mexico Varicella Vaccine Revenue (2020-2031) & (US$ Million)
Figure 35. Europe Varicella Vaccine Sales YoY (2020-2031) & (M Doses)
Figure 36. Europe Varicella Vaccine Revenue YoY (2020-2031) & (US$ Million)
Figure 37. Europe Top 5 Manufacturers Varicella Vaccine Sales Revenue (US$ Million) in 2024
Figure 38. Europe Varicella Vaccine Sales Volume (M Doses) by Type (2020-2031)
Figure 39. Europe Varicella Vaccine Sales Revenue (US$ Million) by Type (2020-2031)
Figure 40. Europe Varicella Vaccine Sales Volume (M Doses) by Application (2020-2031)
Figure 41. Europe Varicella Vaccine Sales Revenue (US$ Million) by Application (2020-2031)
Figure 42. Germany Varicella Vaccine Revenue (2020-2031) & (US$ Million)
Figure 43. France Varicella Vaccine Revenue (2020-2031) & (US$ Million)
Figure 44. U.K. Varicella Vaccine Revenue (2020-2031) & (US$ Million)
Figure 45. Italy Varicella Vaccine Revenue (2020-2031) & (US$ Million)
Figure 46. Russia Varicella Vaccine Revenue (2020-2031) & (US$ Million)
Figure 47. Asia-Pacific Varicella Vaccine Sales YoY (2020-2031) & (M Doses)
Figure 48. Asia-Pacific Varicella Vaccine Revenue YoY (2020-2031) & (US$ Million)
Figure 49. Asia-Pacific Top 8 Manufacturers Varicella Vaccine Sales Revenue (US$ Million) in 2024
Figure 50. Asia-Pacific Varicella Vaccine Sales Volume (M Doses) by Type (2020- 2031)
Figure 51. Asia-Pacific Varicella Vaccine Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 52. Asia-Pacific Varicella Vaccine Sales Volume (M Doses) by Application (2020-2031)
Figure 53. Asia-Pacific Varicella Vaccine Sales Revenue (US$ Million) by Application (2020-2031)
Figure 54. Indonesia Varicella Vaccine Revenue (2020-2031) & (US$ Million)
Figure 55. Japan Varicella Vaccine Revenue (2020-2031) & (US$ Million)
Figure 56. South Korea Varicella Vaccine Revenue (2020-2031) & (US$ Million)
Figure 57. China Taiwan Varicella Vaccine Revenue (2020-2031) & (US$ Million)
Figure 58. India Varicella Vaccine Revenue (2020-2031) & (US$ Million)
Figure 59. Central and South America Varicella Vaccine Sales YoY (2020-2031) & (M Doses)
Figure 60. Central and South America Varicella Vaccine Revenue YoY (2020-2031) & (US$ Million)
Figure 61. Central and South America Top 5 Manufacturers Varicella Vaccine Sales Revenue (US$ Million) in 2024
Figure 62. Central and South America Varicella Vaccine Sales Volume (M Doses) by Type (2021-2031)
Figure 63. Central and South America Varicella Vaccine Sales Revenue (US$ Million) by Type (2020-2031)
Figure 64. Central and South America Varicella Vaccine Sales Volume (M Doses) by Application (2020-2031)
Figure 65. Central and South America Varicella Vaccine Sales Revenue (US$ Million) by Application (2020-2031)
Figure 66. Brazil Varicella Vaccine Revenue (2020-2025) & (US$ Million)
Figure 67. Argentina Varicella Vaccine Revenue (2020-2025) & (US$ Million)
Figure 68. Middle East, and Africa Varicella Vaccine Sales YoY (2020-2031) & (M Doses)
Figure 69. Middle East and Africa Varicella Vaccine Revenue YoY (2020-2031) & (US$ Million)
Figure 70. Middle East and Africa Top 5 Manufacturers Varicella Vaccine Sales Revenue (US$ Million) in 2024
Figure 71. Middle East and Africa Varicella Vaccine Sales Volume (M Doses) by Type (2021-2031)
Figure 72. South America Varicella Vaccine Sales Revenue (US$ Million) by Type (2020-2031)
Figure 73. Middle East and Africa Varicella Vaccine Sales Volume (M Doses) by Application (2020-2031)
Figure 74. Middle East and Africa Varicella Vaccine Sales Revenue (US$ Million) by Application (2020-2031)
Figure 75. GCC Countries Varicella Vaccine Revenue (2020-2025) & (US$ Million)
Figure 76. Turkey Varicella Vaccine Revenue (2020-2025) & (US$ Million)
Figure 77. Egypt Varicella Vaccine Revenue (2020-2025) & (US$ Million)
Figure 78. South Africa Varicella Vaccine Revenue (2020-2025) & (US$ Million)
Figure 79. Varicella Vaccine Industry Chain Mapping
Figure 80. Regional Varicella Vaccine Manufacturing Base Distribution (%)
Figure 81. Global Varicella Vaccine Production Market Share by Region (2020-2031)
Figure 82. Varicella Vaccine Production Process
Figure 83. Regional Varicella Vaccine Production Cost Structure
Figure 84. Channels of Distribution (Direct Vs Distribution)
Figure 85. Bottom-up and Top-down Approaches for This Report
Figure 86. Data Triangulation
Figure 87. Key Executives Interviewed
KEY QUESTIONS ADDRESSED BY THE REPORT
Which companies rank high in the global Varicella Vaccine market?
The top companies in the global Varicella Vaccine market are Merck、GSK、Shanghai Institute.
What is the annual compound growth rate of the global Varicella Vaccine market size from 2025 to 2031?
Which region is expected to have the highest market share?
What was the global market size of Varicella Vaccine in 2025?
What was the global market size of Varicella Vaccine in 2031?
Related Reports
Global Varicella Vaccine Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Varicella Vaccine market size was US$ 5185 million in 2025 and is forecast to reach a readjusted size of US$ 8708 million by 2032 with a CAGR of 7.8% during the forecast period 2026-2032.
Published Date: 2026-01-04
Pages: 79
USD 4250.00
(Single User License)
Global Varicella Vaccine Market Research Report 2026
The global Varicella Vaccine market was valued at US$ 5185 million in 2025 and is anticipated to reach US$ 8708 million by 2032, at a CAGR of 7.8% from 2026 to 2032.
Published Date: 2026-01-04
Pages: 114
USD 2900.00
(Single User License)
Varicella Vaccine- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Varicella Vaccine was estimated to be worth US$ 5185 million in 2025 and is projected to reach US$ 8708 million, growing at a CAGR of 7.8% from 2026 to 2032.
Published Date: 2026-01-04
Pages: 96
USD 3950.00
(Single User License)
Global Varicella Vaccine Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031
In 2024, the global market size of Varicella Vaccine was estimated to be worth US$ 4845 million and is forecast to reach approximately US$ 8137 million by 2031 with a CAGR of 7.8% during the forecast period 2025-2031.
Published Date: 2025-03-28
Pages: 135
USD 5900.00
(Single User License)
Global Varicella Vaccine Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Varicella Vaccine market size was US$ 4845 million in 2024 and is forecast to a readjusted size of US$ 8137 million by 2031 with a CAGR of 7.8% during the forecast period 2025-2031.
Published Date: 2025-03-19
Pages: 77
USD 4250.00
(Single User License)
Varicella Vaccine- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Varicella Vaccine was estimated to be worth US$ 4845 million in 2024 and is forecast to a readjusted size of US$ 8137 million by 2031 with a CAGR of 7.8% during the forecast period 2025-2031.
Published Date: 2025-01-16
Pages: 95
USD 3950.00
(Single User License)
Global Varicella Vaccine Market Research Report 2025
The global market for Varicella Vaccine was valued at US$ 4845 million in the year 2024 and is projected to reach a revised size of US$ 8137 million by 2031, growing at a CAGR of 7.8% during the forecast period.
Published Date: 2025-01-16
Pages: 80
USD 2900.00
(Single User License)
Global Varicella Vaccine Industry Research Report, Growth Trends and Competitive Analysis 2024-2030
Varicella vaccine, also known as chickenpox vaccine, is a vaccine that protects against chickenpox. One dose of vaccine prevents 95% of moderate disease and 100% of severe disease. Two doses of vaccine is more effective than one. If given to those who are not immune within five days of exposure to chickenpox it prevents most cases of disease. Vaccinating a large portion of the population also protects those who are not vaccinated. It is given by injection just under the skin
Published Date: 2024-04-17
Pages: 140
USD 5600.00
(Single User License)
Global Varicella Vaccine Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2024-2030
Varicella vaccine, also known as chickenpox vaccine, is a vaccine that protects against chickenpox. One dose of vaccine prevents 95% of moderate disease and 100% of severe disease. Two doses of vaccine is more effective than one. If given to those who are not immune within five days of exposure to chickenpox it prevents most cases of disease. Vaccinating a large portion of the population also protects those who are not vaccinated. It is given by injection just under the skin
Published Date: 2024-04-16
Pages: 130
USD 5900.00
(Single User License)
Global Varicella Vaccine Market Insights, Forecast to 2030
Varicella vaccine, also known as chickenpox vaccine, is a vaccine that protects against chickenpox. One dose of vaccine prevents 95% of moderate disease and 100% of severe disease. Two doses of vaccine is more effective than one. If given to those who are not immune within five days of exposure to chickenpox it prevents most cases of disease. Vaccinating a large portion of the population also protects those who are not vaccinated. It is given by injection just under the skin
Published Date: 2024-04-07
Pages: 87
USD 4900.00
(Single User License)
Global Varicella Vaccine Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Varicella Vaccine market size was US$ 5185 million in 2025 and is forecast to reach a readjusted size of US$ 8708 million by 2032 with a CAGR of 7.8% during the forecast period 2026-2032.
Published: 2026-01-04
Pages: 79
USD 4250.00 (Single User License)Global Varicella Vaccine Market Research Report 2026
The global Varicella Vaccine market was valued at US$ 5185 million in 2025 and is anticipated to reach US$ 8708 million by 2032, at a CAGR of 7.8% from 2026 to 2032.
Published: 2026-01-04
Pages: 114
USD 2900.00 (Single User License)Varicella Vaccine- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Varicella Vaccine was estimated to be worth US$ 5185 million in 2025 and is projected to reach US$ 8708 million, growing at a CAGR of 7.8% from 2026 to 2032.
Published: 2026-01-04
Pages: 96
USD 3950.00 (Single User License)Global Varicella Vaccine Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031
In 2024, the global market size of Varicella Vaccine was estimated to be worth US$ 4845 million and is forecast to reach approximately US$ 8137 million by 2031 with a CAGR of 7.8% during the forecast period 2025-2031.
Published: 2025-03-28
Pages: 135
USD 5900.00 (Single User License)Global Varicella Vaccine Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Varicella Vaccine market size was US$ 4845 million in 2024 and is forecast to a readjusted size of US$ 8137 million by 2031 with a CAGR of 7.8% during the forecast period 2025-2031.
Published: 2025-03-19
Pages: 77
USD 4250.00 (Single User License)Varicella Vaccine- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Varicella Vaccine was estimated to be worth US$ 4845 million in 2024 and is forecast to a readjusted size of US$ 8137 million by 2031 with a CAGR of 7.8% during the forecast period 2025-2031.
Published: 2025-01-16
Pages: 95
USD 3950.00 (Single User License)Global Varicella Vaccine Market Research Report 2025
The global market for Varicella Vaccine was valued at US$ 4845 million in the year 2024 and is projected to reach a revised size of US$ 8137 million by 2031, growing at a CAGR of 7.8% during the forecast period.
Published: 2025-01-16
Pages: 80
USD 2900.00 (Single User License)Global Varicella Vaccine Industry Research Report, Growth Trends and Competitive Analysis 2024-2030
Varicella vaccine, also known as chickenpox vaccine, is a vaccine that protects against chickenpox. One dose of vaccine prevents 95% of moderate disease and 100% of severe disease. Two doses of vaccine is more effective than one. If given to those who are not immune within five days of exposure to chickenpox it prevents most cases of disease. Vaccinating a large portion of the population also protects those who are not vaccinated. It is given by injection just under the skin
Published: 2024-04-17
Pages: 140
USD 5600.00 (Single User License)Global Varicella Vaccine Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2024-2030
Varicella vaccine, also known as chickenpox vaccine, is a vaccine that protects against chickenpox. One dose of vaccine prevents 95% of moderate disease and 100% of severe disease. Two doses of vaccine is more effective than one. If given to those who are not immune within five days of exposure to chickenpox it prevents most cases of disease. Vaccinating a large portion of the population also protects those who are not vaccinated. It is given by injection just under the skin
Published: 2024-04-16
Pages: 130
USD 5900.00 (Single User License)Global Varicella Vaccine Market Insights, Forecast to 2030
Varicella vaccine, also known as chickenpox vaccine, is a vaccine that protects against chickenpox. One dose of vaccine prevents 95% of moderate disease and 100% of severe disease. Two doses of vaccine is more effective than one. If given to those who are not immune within five days of exposure to chickenpox it prevents most cases of disease. Vaccinating a large portion of the population also protects those who are not vaccinated. It is given by injection just under the skin
Published: 2024-04-07
Pages: 87
USD 4900.00 (Single User License)
CHOOSE LICENSE TYPE
USD 4900.00
USD 7350.00
USD 9800.00
Add to Cart
Buy Now
HAVE A QUESTION?
General Email:
REPORT COVERAGE
DESCRIPTION
OVERVIEW
MARKET SEGMENTATION
CHAPTER OUTLINE
WHY THIS REPORT
QYRESEARCH'S STRENGTHS
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
INTEREST IN THIS REPORT?
Get A Free Sample
Request For Quotation
OR
NEED A CUSTOMIZED REPORT?
Customized Report
Request Sample
Pre-Order Enquiry
Add to Cart
Buy Now